Afmedica, Inc. was founded to develop a sirolimus-impregnated polymer vascular 'wrap' to prevent the excess scarring that can occur inside blood vessels following vascular surgery and adhesions after other surgical procedures. Afmedica was sold to Angiotech Pharmaceuticals, Vancouver, BC, Canada.
Sierra Oncology, Inc.is a clinical stage drug development company advancing next generation DNA Damage Response (DDR) for the treatment of patients with cancer. Sierra Oncology was founded as ProNAi Therapeutics, Inc. and went public July 16, 2015. The name was changed to Sierra Oncology effective January 9, 2017 (NASDAQ: SRRA). For more information please visit sierraoncology.com/.
Armune BioScience, Inc. was formed by the Apjohn Group in 2008 to develop and commercialize blood tests that leverage the warning signals produced by the body’s immune system in response to the onset of cancer. Armune was purchased by Madison, WI based Exact Sciences in early 2018. For further information, see David Esposito’s entry in Our Team and the News section of our website.
Tetra Discovery Partners is developing a platform of drug products to treat cognitive impairment. The Apjohn Group was not involved with founding Tetra, but advised in the formation of a special purpose investment entity to co-lead a $5 million Series A round of financing with the Grand Angels. Included in the full Series A investor list are Dolby Family Ventures, the Alzheimer's Drug Discovery Foundation, and other private investors. For more information please visit tetradiscovery.com.